Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

306 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 306 results

Testing effectiveness (Phase 2)Looking for participantsNCT06830863
What this trial is testing

Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Who this might be right for
EGFR Inhibitor-associated Rash
Azitra Inc. 32
Testing effectiveness (Phase 2)Study completedNCT03544814
What this trial is testing

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Shanghai Chest Hospital 99
Testing effectiveness (Phase 2)Looking for participantsNCT07079475
What this trial is testing

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 200
Testing effectiveness (Phase 2)UnknownNCT03994393
What this trial is testing

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Who this might be right for
EGFR Mutant Advanced Non Small Cell Lung Cancer
University of Sydney 100
Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Early research (Phase 1)Study completedNCT00040781
What this trial is testing

Gefitinib in Treating Children With Refractory Solid Tumors

Who this might be right for
Unspecified Childhood Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 45
Early research (Phase 1)Study completedNCT02476539
What this trial is testing

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 28
Early research (Phase 1)Study completedNCT00681967
What this trial is testing

Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer

Who this might be right for
Head and Neck Cancer
AstraZeneca 30
Testing effectiveness (Phase 2)Study completedNCT00615758
What this trial is testing

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 50
Testing effectiveness (Phase 2)Study completedNCT00600587
What this trial is testing

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Guangdong Provincial People's Hospital 24
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Testing effectiveness (Phase 2)Looking for participantsNCT07326566
What this trial is testing

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Who this might be right for
Glioblastoma (GBM)Newly Diagnosed GlioblastomaGBM+4 more
Black Diamond Therapeutics, Inc. 162
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Testing effectiveness (Phase 2)Ended earlyNCT01522612
What this trial is testing

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Who this might be right for
Colorectal Cancer Metastatic
European Organisation for Research and Treatment of Cancer - EORTC 5
Testing effectiveness (Phase 2)Study completedNCT03623750
What this trial is testing

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Instituto Oncológico Dr Rosell 23
Early research (Phase 1)Study completedNCT00083057
What this trial is testing

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Cancer
National Institutes of Health Clinical Center (CC) 30
Testing effectiveness (Phase 2)Study completedNCT00922584
What this trial is testing

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Who this might be right for
Non-Small Cell Lung Cancer
Chinese Society of Lung Cancer 65
Not applicableUnknownNCT01697163
What this trial is testing

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC
Severance Hospital 155
Testing effectiveness (Phase 2)Ended earlyNCT00445549
What this trial is testing

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms
National Cancer Institute (NCI) 12
Large-scale testing (Phase 3)UnknownNCT02824458
What this trial is testing

Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Sun Yat-sen University 246
Load More Results